Listed

Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2012

Filed with the SEC on Nov 2, 2012 and accepted by EDGAR at Nov 2, 2012, 17:00 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2012-07-01 to 2012-09-30$12.5mus-gaap:SalesRevenueNet
Revenue9 months2012-01-01 to 2012-09-30$35.2mus-gaap:SalesRevenueNet
Cost of revenue3 months2012-07-01 to 2012-09-30$921.9kus-gaap:CostOfGoodsSold
Cost of revenue9 months2012-01-01 to 2012-09-30$2.9mus-gaap:CostOfGoodsSold
Research and development3 months2012-07-01 to 2012-09-30$1.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2012-01-01 to 2012-09-30$4.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2012-07-01 to 2012-09-30$3.0mus-gaap:OperatingIncomeLoss
Operating income9 months2012-01-01 to 2012-09-30$5.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2012-07-01 to 2012-09-30$17.2kus-gaap:InterestExpense
Interest expense9 months2012-01-01 to 2012-09-30$56.4kus-gaap:InterestExpense
Income tax3 months2012-07-01 to 2012-09-30$1.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2012-01-01 to 2012-09-30$1.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2012-07-01 to 2012-09-30$1.9mus-gaap:NetIncomeLoss
Net income9 months2012-01-01 to 2012-09-30$4.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2012-07-01 to 2012-09-30$0.10us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2012-01-01 to 2012-09-30$0.20us-gaap:EarningsPerShareDiluted
Basic EPS3 months2012-07-01 to 2012-09-30$0.10us-gaap:EarningsPerShareBasic
Basic EPS9 months2012-01-01 to 2012-09-30$0.20us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2012-07-01 to 2012-09-3019,670,741 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2012-01-01 to 2012-09-3019,969,051 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2012-01-01 to 2012-09-30$5.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2012-01-01 to 2012-09-30$293.7kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2012-01-01 to 2012-09-30$6.8mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2012-09-30$50.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-09-30$86.8mus-gaap:AssetsCurrent
Total assetsAt period end2012-09-30$96.9mus-gaap:Assets
Current liabilitiesAt period end2012-09-30$8.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-09-30$13.6mus-gaap:Liabilities
Shareholders' equityAt period end2012-09-30$83.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-12-449319. Last ingested by Listed: Nov 14, 2026, 23:39 ET. Listed shows no prices and gives no investment advice.